Erratum: Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer (International Journal of Clinical Oncology DOI: 10.1007/s10147-010-0034-0);Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer

International Journal of Clinical Oncology

Volumn 15, Issue 2, 2010, Pages 161-165

  Ono, Akira ^a   Naito, Tateaki ^a   Murakami, Haruyasu ^a   Takahashi, Toshiaki ^a   Nakamura, Yukiko ^a   Tsuya, Asuka ^a   Kaira, Kyoichi ^a   Igawa, Satoshi ^a   Shukuya, Takehiro ^a   Tamiya, Akihiro ^a   Kaira, Rieko ^a   Endo, Masahiro ^a   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Chemotherapy failure; NSCLC; S 1; Third line treatment

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; AMRUBICIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; GEMCITABINE; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BODY SURFACE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LACRIMATION; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PIGMENT DISORDER; PNEUMONIA; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

EID: 77950929501     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-010-0076-3     Document Type: Erratum

References (14)

1. JH Schiller D Harrington CP Belani, et al. 2002 Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 92 98 10.1056/NEJMoa011954 1:CAS:528:DC%2BD38Xkt1OlsQ%3D%3D 11784875 (Pubitemid 34438899)
2. Y Ohe Y Ohashi K Kubota, et al. 2007 Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan Ann Oncol 18 317 323 10.1093/annonc/mdl377 1:STN:280:DC%2BD2s%2Fotlaqsw%3D%3D 17079694 (Pubitemid 46323100)
3. FA Shepherd J Dancey R Ramlau, et al. 2000 Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2095 3013 1:CAS:528:DC%2BD3cXktVyjsLc%3D 10811675
4. FA Shepherd J Rodrigues Pereira T Ciuleanu, et al. 2005 Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123 132 10.1056/NEJMoa050753 1:CAS:528:DC%2BD2MXmtFaksbo%3D 16014882 (Pubitemid 41058344)
5. ES Kim V Hirsh T Mok, et al. 2008 Phase III randomized, open-label, parallel-group study of oral gefitinib (IRESSA) versus intravenous docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who have previously received platinum-based chemotherapy (INTEREST) Lancet 372 1809 1818 10.1016/S0140-6736(08)61758-4 1:CAS:528:DC%2BD1cXhsVWhtbjM 19027483
6. N Thatcher A Chang P Parikh, et al. 2005 Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 1527 1537 10.1016/S0140-6736(05)67625-8 1:CAS:528:DC%2BD2MXhtFKhsbfP 16257339 (Pubitemid 41540110)
7. M Ando I Okamoto N Yamamoto, et al. 2006 Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib J Clin Oncol 24 2549 2556 10.1200/JCO.2005.04.9866 1:CAS:528:DC%2BD28XmtVOmtrc%3D 16735708 (Pubitemid 46630633)
8. T Shirasaka Y Shimamoto M Fukushima 1993 Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its anticancer activity in rats Cancer Res 53 4004 4009 1:CAS:528:DyaK3sXmtFKqsrk%3D 7689420
9. S Fujii Y Shimamoto H Ohshima, et al. 1989 Effect of the plasma concentration of 5-fluorouracil and the duration of continuous venous infusion of 5-fluorouracil with an inhibitor of 5-fluorouracil degradations on Yoshida sarcoma in rats Jpn J Cancer Res 80 167 172 1:CAS:528:DyaL1MXhvVGmsr0%3D 2498251
10. GD Heggie JP Sommadossi DS Cross, et al. 1987 Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile Cancer Res 47 2203 2206 1:STN:280:DyaL2s7lvFaqtw%3D%3D 3829006
11. K Tatsumi M Fukushima T Shirasaka, et al. 1987 Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts Jpn J Cancer Res 78 748 755 1:CAS:528:DyaL2sXlvFSntL8%3D 3114201
12. T Takechi K Nakano J Uchida, et al. 1997 Anticancer activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rat Cancer Chemother Pharmacol 39 205 211 10.1007/s002800050561 1:CAS:528:DyaK2sXis1ajsL4%3D 8996521 (Pubitemid 26414256)
13. M Kawahara K Furuse Y Segawa, et al. 2001 Phase II study of S-1, a novel oral fluorouracil, in advanced non-small cell lung cancer Br J Cancer 85 939 943 10.1054/bjoc.2001.2031 1:CAS:528:DC%2BD3MXot1SktLg%3D 11592762 (Pubitemid 33015993)
14. DG Pfister DH Johnson CG Azzoli, et al. 2004 American Society of Clinical Oncology Treatment Of Unresectable Non-Small-Cell Lung Cancer Guideline: update 2003 J Clin Oncol 22 330 353 10.1200/JCO.2004.09.053 14691125 (Pubitemid 41095099)